Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03549000




Registration number
NCT03549000
Ethics application status
Date submitted
25/05/2018
Date registered
7/06/2018
Date last updated
18/10/2023

Titles & IDs
Public title
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Scientific title
A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.
Secondary ID [1] 0 0
2018-000153-51
Secondary ID [2] 0 0
CNZV930X2101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-small Cell Lung Cancer (NSCLC) 0 0
Triple Negative Breast Cancer (TNBC) 0 0
Pancreatic Ductal Adenocarcinoma (PDAC) 0 0
Colorectal Cancer Microsatellite Stable (MSS) 0 0
Ovarian Cancer 0 0
Renal Cell Carcinoma (RCC) 0 0
Metastatic Castration Resistant Prostate Cancer (mCRPC) 0 0
Condition category
Condition code
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - NZV930
Other interventions - PDR001
Treatment: Drugs - NIR178

Experimental: NZV930 Monotherapy - Single Agent NZV930

Experimental: NZV930 with PDR001 Doublet Therapy - Combination of NZV930 with PDR001

Experimental: NZV930 with NIR178 Doublet Therapy - Combination of NZV930 with NIR178

Experimental: NZV930 with NIR178 & PDR001 Triplet Therapy - Combination of NZV930 with NIR178 and PDR001


Other interventions: NZV930
NZV930, Specified dose on specified days, intravenous (IV)

Other interventions: PDR001
PDR001, Specified dose on specified days, intravenous (IV)

Treatment: Drugs: NIR178
NIR178 Specified dose on specified days, Orally
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of participants with adverse events as a measure of safety and tolerability of the NZV930 in combination with PDR001 and/or NIR178
Timepoint [1] 0 0
3 years
Secondary outcome [1] 0 0
Overall response rate (ORR)
Timepoint [1] 0 0
3 years
Secondary outcome [2] 0 0
Clinical Benefit Rate (CBR)
Timepoint [2] 0 0
3 years
Secondary outcome [3] 0 0
Progression Free Survival (PFS)
Timepoint [3] 0 0
3 years
Secondary outcome [4] 0 0
Serum concentration vs. time profiles of NZV930 (free drug) and PDR001.
Timepoint [4] 0 0
3 years
Secondary outcome [5] 0 0
Plasma concentration vs. time profiles for NIR178 and derived PK parameters
Timepoint [5] 0 0
3 years
Secondary outcome [6] 0 0
To assess the immunogenicity of NZV930 and PDR001
Timepoint [6] 0 0
3 years

Eligibility
Key inclusion criteria
Adult men & women = 18 years of age Histologically confirmed advanced malignancies with
documented progression following standard therapy, or for whom, in the opinion of the
investigator, no appropriate standard therapy exists.

Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy
according to the treating institution's guidelines. The patient must be willing to undergo
a new tumor biopsy at screening and during treatment.

ECOG performance status 0-2 and in the opinion of the investigator, likely to complete at
least 56 days of treatment.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Symptomatic or uncontrolled Brain metastases requiring concurrent treatment, inclusive of
but not limited to surgery, radiation and/or corticosteroids.

Patients with treated symptomatic brain metastases should be neurologically stable for 4
weeks post-treatment prior to study entry and at doses of <10 mg per day prednisolone or
equivalent for at least 2 weeks before administration of any study treatment.

Patients who required discontinuation of treatment due to treatment-related toxicities with
prior immunotherapy.

Patients previously treated with anti-CD73 treatment and/or adenosine receptor A2a (A2aR)
inhibitors.

Active, previously documented, or suspected autoimmune disease within the past 2 years.

Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone
replacement, psoriasis not requiring systemic treatment or conditions not expected to recur
should not be excluded. Additionally, patients previously exposed to anti-PD-1/PD-L1
treatment who are adequately treated for skin rash or with replacement therapy for
endocrinopathies should not be excluded.

History of or current drug-induced interstitial lung disease or pneumonitis grade = 2.

Impaired cardiovascular function or clinically significant cardiovascular disease,
including any of the following: Clinically significant and/or uncontrolled heart disease
such as congestive heart failure requiring treatment (NYHA Grade = 2), uncontrolled
hypertension or clinically significant arrhythmia Patients with corrected QT using the
Fridericia's correction (QTcF) > 470 msec for females or >450 msec for males, on screening
ECG or congenital long QT syndrome Acute myocardial infarction or unstable angina < 3
months prior to study entry History of stroke or transient ischemic event requiring medical
therapy Symptomatic claudication Infection: HIV infection, Active HBV or HCV infection (per
institutional guidelines). Patients with chronic HBV or HCV disease that is controlled
under antiviral therapy are allowed in the expansion but not in the escalation, Known
history of tuberculosis Infection requiring systemic antibiotic therapy. Patients requiring
systemic antibiotics for infection must have completed treatment before screening is
initiated.

Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For
cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and nitrosoureas, 6
weeks is indicated as washout period. For patients receiving anticancer immunotherapies, 4
weeks is indicated as the washout period.

Systemic chronic steroid therapy (= 10 mg/day prednisone or equivalent) or any
immunosuppressive therapy, other than replacement dose steroids in the setting of adrenal
insufficiency, within 7 days of the first dose of study treatment. Topical, inhaled, nasal,
and ophthalmic steroids are allowed

Other protocol-defined inclusion/exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
18/07/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
17/10/2022
Sample size
Target
Accrual to date
Final
127
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Melbourne
Recruitment postcode(s) [1] 0 0
3000 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
Texas
Country [3] 0 0
Canada
State/province [3] 0 0
Ontario
Country [4] 0 0
Canada
State/province [4] 0 0
Quebec
Country [5] 0 0
Japan
State/province [5] 0 0
Tokyo
Country [6] 0 0
Singapore
State/province [6] 0 0
Singapore
Country [7] 0 0
Spain
State/province [7] 0 0
Comunidad Valenciana
Country [8] 0 0
Spain
State/province [8] 0 0
Madrid
Country [9] 0 0
United Kingdom
State/province [9] 0 0
Surrey

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor
activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178,
in patients with advanced cancers
Trial website
https://clinicaltrials.gov/ct2/show/NCT03549000
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03549000